Sage Therapeutics (SAGE) Zulresso Pricing Better Than Expected - Guggenheim
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $205.00 price target on Sage Therapeutics (NASDAQ: SAGE) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
